Murphy G, Ragde H, Kenny G, Barren R, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T
Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, WA 98125-7001, USA.
Anticancer Res. 1995 Jul-Aug;15(4):1473-9.
PSA (prostate specific antigen) and PSMA (prostate specific membrane antigen) serum levels were determined in over 235 prostate cancer patients from 8 different United States clinical urological cancer centers. The clinical data were not known until after the serum assay results were shared with all participants to attempt to eliminate possible clinical bias. PSA values are useful in the clinical diagnosis and staging of prostate cancer patients, and generally fall to low values in response to effective treatment, e.g., surgery, hormones, radiation, chemotherapy. PSMA values are not related to clinical stage but if elevated can fall in response to effective treatments. In contrast, PSMA values can be elevated post-treatment in the presence of very low PSA levels (0.01 to 0.00). The elevated PSMA levels predicted a state of clinical progression or clinical resistance in most cases (> 70%). PSMA levels in this study were of better prognostic value than PSA.
对来自美国8个不同临床泌尿外科癌症中心的235例以上前列腺癌患者测定了血清前列腺特异性抗原（PSA）和前列腺特异性膜抗原（PSMA）水平。在将血清检测结果告知所有参与者以试图消除可能的临床偏倚之后，才得知临床数据。PSA值在前列腺癌患者的临床诊断和分期中有用，并且通常在有效治疗（例如手术、激素、放疗、化疗）后降至低值。PSMA值与临床分期无关，但如果升高，在有效治疗后会下降。相比之下，在PSA水平非常低（0.01至0.00）的情况下，治疗后PSMA值可能会升高。在大多数情况下（>70%），升高的PSMA水平预示着临床进展或临床抵抗状态。本研究中PSMA水平比PSA具有更好的预后价值。
